Enrolling now: quizartinib plus standard therapy for newly-diagnosed AML

The phase 3 QuANTUM-Wild study is assessing the use of quizartinib plus standard induction/consolidation chemotherapy and maintenance therapy in newly-diagnosed patients with FLT3-ITD-negative acute myeloid leukemia (AML).

Phase 3 MIDAS trial assesses MRD-driven approach to consolidation, maintenance therapy in myeloma

A phase 3 study is assessing a measurable residual disease (MRD)-driven consolidation and maintenance strategy for patients with newly diagnosed multiple myeloma (NDMM).

Early palliative care integration does not reduce MM patients’ healthcare utilization

Early integration of palliative care does not reduce the use of healthcare resources by patients with newly diagnosed multiple myeloma (MM) compared to patients who received standard care, according to […]